Neuberger Berman Group
CAI

Neuberger Berman Group’s Caris Life Sciences CAI Stock Holding History

Neuberger Berman Group’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.2M Sell
3,590,586
-210,336
-6% -$4.6M 0.05% 426
2025
Q4 		$103M Sell
3,800,922
-544,120
-13% -$15.3M 0.08% 307
2025
Q3 		$109M Sell
4,345,042
-1,894,478
-30% -$60.4M 0.08% 317
2025
Q2 		$167M Buy
+6,239,520
New +$168M 0.13% 191

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Neuberger Berman Group's CAI Position: Q1 2026 in Review

Neuberger Berman Group reduced its Caris Life Sciences (CAI) stake by 5.5% in Q1 2026, selling an estimated $4.6M and leaving 3,590,586 shares worth $64.2M. The position accounts for 0.05% of the portfolio, ranked #426.

Neuberger Berman Group first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $167M in Q2 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Neuberger Berman Group held 3,590,586 shares of Caris Life Sciences worth $64.2M as of Q1 2026.
  • Neuberger Berman Group sold 210,336 Caris Life Sciences shares in Q1 2026, an estimated $4.6M.
  • Caris Life Sciences made up 0.05% of Neuberger Berman Group's portfolio in Q1 2026, its #426 holding.
  • Neuberger Berman Group first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • Neuberger Berman Group's Caris Life Sciences position peaked at $167M in Q2 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.